Literature DB >> 26754959

Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma.

Joycelyn J X Lee1, Alexandre Chan2,3, Tiffany Tang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26754959     DOI： 10.3109/0284186X.2015.1125017

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  25 in total

1.  Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model.

Authors:  Li-Li Guo; Gang-Cheng Wang; Peng-Jie Li; Cui-Mei Wang; Lin-Bo Liu
Journal:  Exp Ther Med       Date:  2018-04-23       Impact factor: 2.447

Review 2.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

3.  Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.

Authors:  Gregory R Stroh; Tobias Peikert; Patricio Escalante
Journal:  Cancer Immunol Immunother       Date:  2021-03-26       Impact factor: 6.968

4.  Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.

Authors:  A Singh; A Mohan; A B Dey; D K Mitra
Journal:  Clin Exp Immunol       Date:  2016-11-24       Impact factor: 4.330

5.  PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques.

Authors:  Keith D Kauffman; Shunsuke Sakai; Nickiana E Lora; Sivaranjani Namasivayam; Paul J Baker; Olena Kamenyeva; Taylor W Foreman; Christine E Nelson; Deivide Oliveira-de-Souza; Caian L Vinhaes; Ziv Yaniv; Cecilia S Lindestam Arleham; Alessandro Sette; Gordon J Freeman; Rashida Moore; Alan Sher; Katrin D Mayer-Barber; Bruno B Andrade; Juraj Kabat; Laura E Via; Daniel L Barber
Journal:  Sci Immunol       Date:  2021-01-15

6.  CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease.

Authors:  Shunsuke Sakai; Keith D Kauffman; Michelle A Sallin; Arlene H Sharpe; Howard A Young; Vitaly V Ganusov; Daniel L Barber
Journal:  PLoS Pathog       Date:  2016-05-31       Impact factor: 6.823

7.  Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes.

Authors:  Chin-Chung Shu; Jann-Yuan Wang; Ming-Fang Wu; Chen-Tu Wu; Hsin-Chih Lai; Li-Na Lee; Bor-Luen Chiang; Chong-Jen Yu
Journal:  Sci Rep       Date:  2017-02-07       Impact factor: 4.379

8.  Circulating HLA-DR+CD4+ effector memory T cells resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis.

Authors:  Asma Ahmed; Vasista Adiga; Soumya Nayak; J Anto Jesuraj Uday Kumar; Chirag Dhar; Pravat Nalini Sahoo; Bharath K Sundararaj; George D Souza; Annapurna Vyakarnam
Journal:  PLoS Pathog       Date:  2018-09-19       Impact factor: 6.823

9.  Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report.

Authors:  Wan He; Xiangmei Zhang; Wenwen Li; Cheng Kong; Yuanyang Wang; Lianyu Zhu; Ruilian Xu; Guofang Deng; Peize Zhang
Journal:  Onco Targets Ther       Date:  2018-10-24       Impact factor: 4.147

Review 10.  Immune Checkpoint Inhibitors in Special Populations.

Authors:  Qianyun Shan; Hongyang Lu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.